DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: No-carrier-added [.sup.18 F]-N-fluoroalkylspiroperidols

Abstract

There is disclosed radioligands labeled with the position emitting radionuclide [.sup.18 F] suitable for dynamic study in living humans with position emission transaxial tomography. These new [.sup.18 F]-N-fluoroalkylspiroperidols, wherein the alkyl group contains from 2-6 carbon atoms, exhibit extremely high affinity for the dopamine receptors and provide enhanced uptake and retention in the brain concomitant with reduced radiation burden. These characteristics all combine to make these new radioligands useful for mapping dopamine receptors in normal and disease states in the living brain. Additionally, a new synthetic procedure for these radioligands as well as a new procedure for preparing the radiolabeled alkyl halide alkylating reagents are also disclosed.

Inventors:
 [1];  [2];  [3];  [3]
  1. East Setauket, NY
  2. Setauket, NY
  3. Upton, NY
Issue Date:
Research Org.:
Associated Universities, Inc., Upton, NY (United States)
OSTI Identifier:
867124
Patent Number(s):
4871527
Assignee:
United States of America as represented by United States (Washington, DC)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07B - GENERAL METHODS OF ORGANIC CHEMISTRY
DOE Contract Number:  
AC02-76CH00016
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
no-carrier-added; 18; -n-fluoroalkylspiroperidols; disclosed; radioligands; labeled; position; emitting; radionuclide; suitable; dynamic; study; living; humans; emission; transaxial; tomography; alkyl; contains; 2-6; carbon; atoms; exhibit; extremely; affinity; dopamine; receptors; provide; enhanced; uptake; retention; brain; concomitant; reduced; radiation; burden; characteristics; combine; useful; mapping; normal; disease; additionally; synthetic; procedure; preparing; radiolabeled; halide; alkylating; reagents; carbon atoms; carbon atom; provide enhanced; dopamine receptor; alkyl halide; transaxial tomography; emission transaxial; emitting radionuclide; dynamic study; living human; living humans; /424/999/

Citation Formats

Shiue, Chyng-Yann, Wolf, Alfred P, Bai, Lan-Qin, and Teng, Ren-Tui. No-carrier-added [.sup.18 F]-N-fluoroalkylspiroperidols. United States: N. p., 1989. Web.
Shiue, Chyng-Yann, Wolf, Alfred P, Bai, Lan-Qin, & Teng, Ren-Tui. No-carrier-added [.sup.18 F]-N-fluoroalkylspiroperidols. United States.
Shiue, Chyng-Yann, Wolf, Alfred P, Bai, Lan-Qin, and Teng, Ren-Tui. Sun . "No-carrier-added [.sup.18 F]-N-fluoroalkylspiroperidols". United States. https://www.osti.gov/servlets/purl/867124.
@article{osti_867124,
title = {No-carrier-added [.sup.18 F]-N-fluoroalkylspiroperidols},
author = {Shiue, Chyng-Yann and Wolf, Alfred P and Bai, Lan-Qin and Teng, Ren-Tui},
abstractNote = {There is disclosed radioligands labeled with the position emitting radionuclide [.sup.18 F] suitable for dynamic study in living humans with position emission transaxial tomography. These new [.sup.18 F]-N-fluoroalkylspiroperidols, wherein the alkyl group contains from 2-6 carbon atoms, exhibit extremely high affinity for the dopamine receptors and provide enhanced uptake and retention in the brain concomitant with reduced radiation burden. These characteristics all combine to make these new radioligands useful for mapping dopamine receptors in normal and disease states in the living brain. Additionally, a new synthetic procedure for these radioligands as well as a new procedure for preparing the radiolabeled alkyl halide alkylating reagents are also disclosed.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {1989},
month = {1}
}